Log In
Print
BCIQ
Print
Print this Print this
 

BPX-201

  Manage Alerts
Collapse Summary General Information
Company Bellicum Pharmaceuticals Inc.
DescriptionGenetically modified, autologous dendritic cells targeting prostate cancer cells
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today